News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The company will also share results in two additional posters for deuruxolitinib
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Combined entity is better positioned to compete in increasingly competitive generics industry
HaystackAnalytics is engaged in the business of developing genomic analysis software
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Subscribe To Our Newsletter & Stay Updated
